EPI-CALL™ provides an integrated report that includes analysis of alternate promoters, gene fusion, and genomic information through the supplementation of genomic information.

With our proprietary technology, we are able to utilise the same number of slides to obtain both genomic and epigenomic information. Recent clinical studies have demonstrated that Alternate Promoter Score (APS) correlates well with response to immunotherapeutic agents, such as ICIs, and therefore could be used as a novel predictive biomarker for immunotherapy.

APS is calculated through a proprietary algorithm to provide predictive information that may be used to inform systemic treatment decisions with immunotherapy and/or chemotherapy. It is a score that ranges from 0-1 and is calculated from the data analysis of ~5,000 alternate promoters. The test has a demonstrated accuracy of 95% accuracy for Gastric Cancer and may be applicable to multiple Asian cancer types.

Using WTS, we can also make gene fusion calls and use other bioinformatics pipelines to analyse the data.

EPI-CALL™ complements current NGS tests today by incorporating epigenomic information with genomic information. The test provides a comprehensive report by identifying immunotherapy responders and gives actionable insights to clinicians with data-driven analytics.